[1] COTTER T G,RINELLA M.Nonalcoholic Fatty Liver Disease 2020:The State of the Disease[J].Gastroenterology,2020,158(7):1851-1864. [2] WANG X J,MALHI H.Nonalcoholic fatty liver disease[J].Ann Intern Med,2018,169(9):ITC65-ITC80. [3] SPOREA I,POPESCU A,DUMITRACU D,et al.Nonalcoholic fatty liver disease:Status quo[J].J Gastrointestin Liver Dis,2018,27(4):439-448. [4] 李军祥,陈誩,王允亮.非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2017,25(11):805-811. [5] RU J,LI P,WANG J,et al.TCMSP:A database of systems pharmacology for drug discovery from herbal medicines[J].J Cheminform,2014,6:13. [6] BIJLSMA J W,BERENBAUM F,LAFEBER F P.Osteoarthritis:An update with relevance for clinical practice[J].Lancet,2011,377(9783):2115-2126. [7] XU H Y,LIU Z M,FU Y,et al.Exploiture and application of an internet-based computation platform for integrative pharmacology of traditional Chinese chronic obstructive pulmonary disease[J].Sci Rep,2015,5(8):15290-15296. [8] CHEN X,JI Z L,CHEN Y Z.TTD:Therapeutic target database[J].Nucleic Acids Res,2002,30(1):412-415. [9] WISHART D S,KNOX C,GUO A C,et al.DrugBank:A comprehensive resource for in silico drug discovery and exploration[J].Nucleic Acids Res,2006,34:668-672. [10] PINERO J,BRAVO À,QUERALT-ROSINACH N,et al.DisGeNET:A comprehensive platform integrating information on human disease-associated genes and variants[J].Nucleic Acids Res,2017,45(D1):D833-D839. [11] UNIPROT CONSORTIUM.UniProt:The universal protein knowledgebase in 2021[J].Nucleic Acids Res,2021,49(D1):D480-D489. [12] FONSEKA P,PATHAN M,CHITTI S V,et al.FunRich enables enrichment analysis of OMICs datasets[J].J Mol Biol,2021:166747. [13] PATHAN M,KEERTHIKUMAR S,CHISANGA D,et al.A novel community driven software for functional enrichment analysis of extracellular vesicles data[J].J Extracellular Vesicles,2017,1:1321455. [14] PATHAN M,KEERTHIKUMAR S,ANG C S,et al.FunRich:A standalone tool for functional enrichment analysis[J].Proteomics,2015, 15:2597-2601. [15] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病防治指南(2018更新版)[J].临床肝胆病杂志,2018,34(5):947-957. [16] 李军祥,陈誩,王允亮.非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2017,25(11):805-811. [17] 王倩. 胃苓汤加减治疗脾虚湿盛型高脂血症的疗效分析[J].临床医药文献电子杂志,2018,5(49):107-108. [18] 杨艳娜. 胃苓汤合多烯磷脂酰胆碱胶囊治疗痰湿质非酒精性脂肪性肝炎42例[J].内蒙古中医药,2015,34(8):64-65. [19] 徐艳芬,李政伟.胃苓汤加减对2型糖尿病脾虚痰湿证胰岛素抵抗的影响[J].山西中医,2021,37(12):14-16. [20] 刘奇,郭宏丽.新加胃苓汤联合肠道微生态调节剂治疗小儿迁延性腹泻的疗效及对患儿肠道微生态的影响[J].海南医学,2020,31(4):459-462. [21] 邬艳波,陈瑞,黄国清,等.加味胃苓汤对肝硬化腹水患者肠道菌群的影响[J].中西医结合肝病杂志,2018,28(6):331-332. [22] 孟动玲. 加味胃苓汤治疗肝硬化腹水的应用基础研究[D].武汉:湖北中医药大学,2016. [23] 于鲁志. 中药甘草抗炎作用药理和临床研究进展[J].光明中医,2017, 32(19):2895-2898. [24] 龚杰,丁岩,干仲元,等.泽泻提取物对大鼠非酒精性脂肪肝的治疗作用[J].中国比较医学杂志,2018,28(7):68-76. [25] YAN Z,MIAO X,ZHANG B,et al.p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease[J].Life Sci,2018, 215:64-72. [26] YAN F J,WANG X,WANG S E,et al.C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD[J].Biochem J,2020,477(3):691-708. [27] WU H,CHEN G,WANG J,et al.TIM-4 interference in Kupffer cells against CCL4-induced liver fibrosis by mediating Akt1/Mitophagy signalling pathway[J].Cell Prolif,2020,53(1):e12731. [28] ZHAO J,QI Y F,YU Y R.STAT3:A key regulator in liver fibrosis[J].Ann Hepatol,2021,21:100224. [29] 张新,陈文娜,宋囡,等.基于分子互作网络探讨丹蒌片干预PI3K/AKT/NF-κB/TNF通路防治非酒精性脂肪肝病的机制[J].中国免疫学杂志,2022,38(11):1324-1332. [30] SONG G,OUYANG G,BAO S.The activation of Akt/PKB signaling pathway and cell survival[J].J Cell Mol Med,2005,9(1):59-71. [31] ENGELMAN J A,LUO J,CANTLEY L C.The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism[J].Nat Rev Genet,2006,7(8):606-619. [32] CARNERO A,BLANCO-APARICIO C,RENNER O,et al.The PTEN/PI3K/AKT signalling pathway in cancer,therapeutic implications[J].Curr Cancer Drug Targets,2008,8(3):187-198. [33] 冯钟文. 基于TLR4/NF-κB和PI3K/Akt信号通路研究香蜂草苷对小鼠非酒精性脂肪肝的作用及其作用机制[D].南宁:广西医科大学,2021. [34] 彭孟云,朱晓宁,汪静.MAPK信号通路与非酒精性脂肪肝关系的研究进展[J].广东医学,2015,36(5):804-806. |